ProCE Banner Activity

Phase I Study of Odronextamab, a Novel Bispecific Antibody Targeting CD3 and CD20, for Patients With Heavily Pretreated B-Cell NHL

Slideset Download
Conference Coverage
Durable CRs observed among patients with highly refractory FL and DLBCL, including those previously receiving CAR T-cell therapy.

Released: December 10, 2020

Expiration: December 09, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology